Basic/Translational Science Survey Section: Kidney Cancer

Erdafitinib in Patients with High- and Intermediate-risk Non-muscle-invasive Bladder Cancer: Final Analysis of THOR-2 Study.

European urology·2025

Adrenal imaging features and associated pathologic diagnoses: A contemporary, longitudinal analysis.

Surgery·2025

Developing biomarkers and methods of risk stratification: Consensus statements from the International Kidney Cancer Symposium North America 2024 Think Tank.

Urologic oncology·2025

Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 study.

The Lancet. Oncology·2025

Impact of postprogression therapies on overall survival: Recommendations from the 2023 kidney cancer association think tank meeting.

Urologic oncology·2024

Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study.

The Lancet. Oncology·2024

Expanding indications for PARP inhibitors in prostate cancer.

Urologic oncology·2026

Quantitative core-level tumor burden and grading in MRI-targeted vs. systematic prostate biopsy: A within-patient paired analysis.

Urologic oncology·2026

Development and validation of a computational histology artificial intelligence-powered prognostic biomarker in muscle-invasive bladder cancer.

Urologic oncology·2026

Predicting long-term metastatic risk after radical prostatectomy: Adding Genomic Prostate Score, grade group, and cribriform size to unfavorable histology burden translates into minimal incremental discrimination.

Urologic oncology·2026

Trans-perineal prostate biopsy-Prognostic factors for "no prostate tissue" in biopsy cores.

Urologic oncology·2026

Benign but burdensome: Complications and management of benign prostatic hyperplasia during active surveillance of prostate cancer in a large cohort.

Urologic oncology·2026

Hydrogel-Nanoparticle Bioactive Platforms for Post-Surgical Prevention of Tumor Recurrence.

Nanomaterials (Basel, Switzerland)·2026

FDA Approval Summary: Erdafitinib for FGFR3-Altered Locally Advanced or Metastatic Urothelial Carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Regulatory cascade of NdpR and NdpR2 in controlling nicotine degradation operons in Sphingomonas melonis TY.

Applied and environmental microbiology·2026

Epidermal growth factor receptor as a target enzyme in cancer therapy: Structural and functional insights from crystallography.

Indian journal of pharmacology·2026

Mitigating Breast Cancer with Intratumoral In Situ pH-responsive Abemaciclib-loaded Novasome Hydrogel.

Journal of drug targeting·2026

Mechanisms and Predisposing Conditions for Statin-Induced New-Onset Type 2 Diabetes Mellitus: A Paradox Relative to Their Pleiotropic Metabolic Effects.

Endocrinology, diabetes & metabolism·2026

Related Experiment Videos

Basic/Translational Science Survey Section: Kidney Cancer

Related Concept Videos

Erdafitinib in Patients with High- and Intermediate-risk Non-muscle-invasive Bladder Cancer: Final Analysis of THOR-2 Study.

Adrenal imaging features and associated pathologic diagnoses: A contemporary, longitudinal analysis.

Developing biomarkers and methods of risk stratification: Consensus statements from the International Kidney Cancer Symposium North America 2024 Think Tank.

Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 study.

Impact of postprogression therapies on overall survival: Recommendations from the 2023 kidney cancer association think tank meeting.

Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study.

Expanding indications for PARP inhibitors in prostate cancer.

Quantitative core-level tumor burden and grading in MRI-targeted vs. systematic prostate biopsy: A within-patient paired analysis.

Development and validation of a computational histology artificial intelligence-powered prognostic biomarker in muscle-invasive bladder cancer.

Predicting long-term metastatic risk after radical prostatectomy: Adding Genomic Prostate Score, grade group, and cribriform size to unfavorable histology burden translates into minimal incremental discrimination.

Trans-perineal prostate biopsy-Prognostic factors for "no prostate tissue" in biopsy cores.

Benign but burdensome: Complications and management of benign prostatic hyperplasia during active surveillance of prostate cancer in a large cohort.

Hydrogel-Nanoparticle Bioactive Platforms for Post-Surgical Prevention of Tumor Recurrence.

FDA Approval Summary: Erdafitinib for FGFR3-Altered Locally Advanced or Metastatic Urothelial Carcinoma.

Regulatory cascade of NdpR and NdpR2 in controlling nicotine degradation operons in Sphingomonas melonis TY.

Epidermal growth factor receptor as a target enzyme in cancer therapy: Structural and functional insights from crystallography.

Mitigating Breast Cancer with Intratumoral In Situ pH-responsive Abemaciclib-loaded Novasome Hydrogel.

Mechanisms and Predisposing Conditions for Statin-Induced New-Onset Type 2 Diabetes Mellitus: A Paradox Relative to Their Pleiotropic Metabolic Effects.

Related Experiment Videos

Basic/Translational Science Survey Section: Kidney Cancer

Related Concept Videos

Related Articles